Lifeloc Technologies, Inc. reported fiscal‑year 2025 revenue of $9.027 million, a 6% increase from $8.538 million in 2024. The growth was driven by higher sales of its core breathalyzer products and incremental revenue from training and certification services, offsetting modest headwinds in other segments.
Gross margin for the year was 40.3%, essentially unchanged from 40.4% in 2024. The company’s management explained that price increases and higher volume helped offset inflationary component costs and tariff impacts, keeping margins stable despite the cost pressures noted in the report.
Net loss widened to $2.470 million in 2025 from $1.053 million in 2024. The increase is largely attributable to a non‑cash valuation allowance for deferred taxes, a one‑time charge that does not affect cash flow. Operating losses have continued for four consecutive years, underscoring ongoing liquidity pressure.
The company highlighted its SpinDetect™ Centrifugal Drug Analyzer as a key driver of future profitability. Dr. Wayne Willkomm, President and CEO, said, "While the whole project has taken more time and resources than we planned, the impact of putting an effective drug detection device into the hands of law enforcement and commercial safety officers is going to be worth all the effort and investment." SpinDetect is slated for commercial launch in 2026, and the company’s cash position has declined while it carries debt, making access to capital critical for continued development.
Lifeloc’s stock began trading on the OTCID tier of the OTC Markets on July 1, 2025, and the company has a history of operating losses. The FY2025 results confirm that while revenue is growing modestly, the company remains in a capital‑intensive phase, with profitability dependent on the successful commercialization of SpinDetect and continued investment in its core breathalyzer business.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.